Pediatrix Medical Group (MD) Q2 Earnings: What To Expect
Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) will be reporting earnings this Tuesday before market open. Here’s what to look for.
Pediatrix Medical Group beat analysts’ revenue expectations last quarter, reporting revenues of $476.2 million, up 3.9% year on year. It was a very strong quarter for the company, with a beat of analysts’ EPS estimates and full-year EBITDA guidance slightly topping analysts’ expectations.
Is Pediatrix Medical Group a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Pediatrix Medical Group’s revenue to grow 1.9% year on year, a reversal from the 7% decrease it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Pediatrix Medical Group rarely misses Wall Street’s revenue estimates.
Looking at Pediatrix Medical Group’s peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. The Ensign Group delivered year-on-year revenue growth of 10.7%, missing analysts’ expectations by 7.9%, and Centene reported revenues up 9.9%, topping estimates by 13.1%. The Ensign Group traded up 5.9% following the results while Centene was down 3.5%.
Read our full analysis of The Ensign Group’s results here and Centene’s results here.
Investors in the healthcare providers & services segment have had steady hands going into earnings, with share prices flat over the last month. Pediatrix Medical Group is down 3.2% during the same time and is heading into earnings with an average analyst price target of $24.50 (compared to the current share price of $26.51).
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.